Kratom & Antidepressants (SSRIs/SNRIs): What Research Shows

Two Risk Dimensions

1. Serotonin Syndrome: Mitragynine shows preclinical hints of serotonin receptor interactions (5-HT2A, 5-HT7). With simultaneous SSRI/SNRI intake, serotonerging activity could summate – risk not definitively established but not excluded. Published case reports describe a possible association.

2. Cytochrome P450 Interaction: Mitragynine may inhibit CYP3A4 and CYP2D6 – the same enzymes metabolising many antidepressants. This could lead to elevated antidepressant blood levels with unpredictable effects.

Conclusion

Anyone prescribed antidepressants with questions about combinations should discuss them with a physician.

This article describes the scientific research status only. It does not replace medical advice. Our products are not intended for consumption.

Legal Notice: This article is for informational purposes only and does not constitute legal advice. The content is not intended to encourage consumption. Laws may change; the applicable regulations and information from official authorities shall prevail. Image source: https://www.kratoein.com/